It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy short term (up to 12 weeks) compared with RISPERIDONE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ inefficacy ‐ short term (up to 12 weeks) compared with QUETIAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early: inefficacy ‐ short term (up to 12 weeks) compared with OLANZAPINE (very low certainty).
It is very uncertain whether FLUPHENAZINE (ORAL) changes leaving the study early ‐ any reason ‐ short term (up to 12 weeks) compared with AMISULPRIDE (very low certainty).
The intervention showed no clear difference in chlamydia prevalence (general population) Outcome was chlamydia test… (low certainty).
It is very uncertain whether the intervention changes delayed open necrosectomy vs. early open necrosectomy (very low certainty).
Prophylactic oxytocin injection (delivered by community health… showed no clear difference in early infant death (0‐3 days) [ compared with control (no injection) (low certainty).
CHLORPROMAZINE showed no clear difference in leaving the study early ‐ due to adverse effects (short term) compared with RESERPINE (moderate certainty).
FLUPHENAZINE DECANOATE showed no clear difference in leaving the study early compared with ORAL NEUROLEPTICS (low certainty).
It is very uncertain whether FLUPHENAZINE DECANAOTE changes leaving the study early compared with FLUPHENAZINE ENANTHATE (very low certainty).
It is very uncertain whether FLUPHENAZINE DECANOATE changes leaving the study early compared with PLACEBO (very low certainty).
Transmyocardial laser revascularization showed no clear difference in early postoperative mortality Deaths in the 30 days after surgery compared with medical treatment (high certainty).
It is very uncertain whether adjunctive lithium + antipsychotics changes acceptability of treatment leaving early due to any reason compared with placebo/no adjunctive treatment + antipsychotics (very low certainty).
Lithium as sole treatment showed no clear difference in acceptability of treatment leaving early due to any reason compared with placebo (low certainty).
It is very uncertain whether lithium changes acceptability of treatment leaving early due to any reason compared with antipsychotics (very low certainty).
SUPPORTIVE THERAPY showed no clear difference in leaving the study early compared with ANY OTHER PSYCHOLOGICAL OR PSYCHOSOCIAL TREATMENT (moderate certainty).
SUPPORTIVE THERAPY showed no clear difference in leaving the study early compared with COGNITIVE BEHAVIOURAL THERAPY (moderate certainty).
It is very uncertain whether SUPPORTIVE THERAPY changes leaving the study early compared with FAMILY THERAPY (very low certainty).
It is very uncertain whether SUPPORTIVE THERAPY changes leaving the study early compared with PSYCHOEDUCATION (very low certainty).